242 related articles for article (PubMed ID: 30693698)
1. [Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide].
Hao R; Su L; Shao Y; Bu N; Ma L; Naranmandura H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2018 May; 47(5):541-551. PubMed ID: 30693698
[TBL] [Abstract][Full Text] [Related]
2. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
[TBL] [Abstract][Full Text] [Related]
3. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As
Huang X; Yang Y; Zhu D; Zhao Y; Wei M; Li K; Zhu HH; Zheng X
Cell Mol Life Sci; 2022 May; 79(6):319. PubMed ID: 35622143
[TBL] [Abstract][Full Text] [Related]
4. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
[TBL] [Abstract][Full Text] [Related]
7. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Tomita A; Kiyoi H; Naoe T
Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
[TBL] [Abstract][Full Text] [Related]
9. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
11. Irreversibility of arsenic trioxide induced PML/RARα fusion protein solubility changes.
Maimaitiyiming Y; Shao YM; Chen WZ; Jiang Y; Bu N; Ma LY; Wang QQ; Lu XY; Naranmandura H
Metallomics; 2019 Dec; 11(12):2089-2096. PubMed ID: 31670356
[TBL] [Abstract][Full Text] [Related]
12. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells.
Müller S; Miller WH; Dejean A
Blood; 1998 Dec; 92(11):4308-16. PubMed ID: 9834237
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
14. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
15. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
[TBL] [Abstract][Full Text] [Related]
16. Identification of a point mutation PML
Zhao S; Shi P; Zhong Q; Shao S; Huang Y; Sun Y; Wu C; Zhu HH
Biochem Biophys Res Commun; 2019 Apr; 511(3):518-523. PubMed ID: 30824184
[TBL] [Abstract][Full Text] [Related]
17. The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
Andre C; Guillemin MC; Zhu J; Koken MH; Quignon F; Herve L; Chelbi-Alix MK; Dhumeaux D; Wang ZY; Degos L; Chen Z; de The H
Exp Cell Res; 1996 Dec; 229(2):253-60. PubMed ID: 8986606
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
19. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
20. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
